NeuroScientific Advances StemSmart™ Program as Crohn’s Trial Prep Gathers Pace

The latest announcement is out from Neuroscientific Biopharmaceuticals Ltd. ( (AU:NSB) ).

NeuroScientific Biopharmaceuticals has advanced clinical and operational development of its StemSmart™ mesenchymal stem cell platform during the December 2025 quarter, with a particular focus on treating patients with severe, treatment-resistant fistulising Crohn’s disease through Australia’s Special Access Scheme. The company reported that three of four patients in the first cohort achieved a clinical response, providing early validation of the technology and informing the design of a planned Phase 2 trial in refractory Crohn’s disease expected to start in 2026. In parallel, NeuroScientific has appointed a Clinical & Scientific Advisory Board, progressed manufacturing technology transfer and scale-up with Q-Gen to bolster future clinical and supply readiness, and ended the quarter with approximately $6.4 million in cash, supporting its near-term clinical development plans and reinforcing its positioning as an emerging player in advanced cell therapies for inflammatory bowel disease.

The most recent analyst rating on (AU:NSB) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Neuroscientific Biopharmaceuticals Ltd. stock, see the AU:NSB Stock Forecast page.

More about Neuroscientific Biopharmaceuticals Ltd.

NeuroScientific Biopharmaceuticals Limited is an Australian biotechnology company focused on developing novel therapies for immune-mediated inflammatory diseases. Its lead asset is the proprietary StemSmart™ mesenchymal stem cell platform, aimed at addressing severe conditions with high unmet medical need such as fistulising Crohn’s disease.

Average Trading Volume: 391,401

Technical Sentiment Signal: Strong Buy

Current Market Cap: A$49.89M

For detailed information about NSB stock, go to TipRanks’ Stock Analysis page.